| Table 2. Outcomes in Groups Lu Group Fo | |||
| Group Lu | Group Fo | p-value | |
| Length of stimulation (days) | 11.3±3.6 | 8.1±2.8 | <0.001 |
| Dosage of HMG(IU) | 2336.8±848.8 | 1388.2±731.8 | <0.001 |
| No. of retrieved oocytes | 2.7±2.1 | 2.4±1.5 | 0.085 |
| Metaphase II oocyte rate n(%) | 325/416 (78.1) | 374/551 (67.9) | <0.001 |
| Fertilization rate n(%) | 349/416 (83.9) | 441/551 (80.0) | 0.125 |
| Cleavage rate n(%) | 345/349 (98.9) | 437/441 (99.1) | 0.739 |
| Top-quality embryo rate n(%) | 211/307 (68.7) | 255/382 (66.8) | 0.582 |
| ET clinical pregnancy raten(%) | - | 31/79 (39.2)a | 0.392 |
| FET clinical pregnancy rate n(%) | 31/109 (28.4) | 31/94 (33.0) | 0.484 |
| ET miscarriage rate n(%) | - | 9/31 (29.0)b | 0.374 |
| FET miscarriage rate n(%) | 5/31 (16.1) | 6/31 (19.4) | 0.740 |
| ET live birth rate n(%) | - | 20/79 (25.3)c | 0.974 |
| FET live birth rate n(%) | 25/109 (22.9) | 24/94 (25.5) | 0.666 |
| NS = not significant; No.= number; a = comparison of clinical pregnancy rates between ET cycles and FET cycles in Group Fo; b = comparison of miscarriage rates between ET cycles and FET cycles in Group Fo; c = comparison of live birth rates between ET cycles and FET cycles in Group Fo. |
|||